Denosumab

USDailyMed:Denosumab AU:D M05BX04(WHO) AU:S4(Prescription only)CA:℞-only/Schedule DUS:℞-onlyEU:Rx-only 615258-40-7 DB06643 none 4EQZ6YO2HI D03684 ChEMBL1237023 Denosumab, sold under the trade nameProliaamong others, as well as manybiosimilars, is a humanmonoclonal antibodyused for the treatment ofosteoporosis, treatment-induced bone loss,metastasesto bone, andgiant cell tumor of bone. The most common side effects arejointandmuscle painin the arms or legs. Denosumab is aninhibitor of RANKL (receptor activator of nuclear factor kappa-Β ligand),which works by decreasing the development ofosteoclasts, which are cells thatbreak down bone.‍‍‍‍‍‍​​​‍​​​​​​ Denosumab is a human monoclonal IgG2 antibody that targets the protein RANKL, which is essential for the formation, function and survival of osteoclasts, the cell type responsible for bone resorption.Denosumab binds to RANKL with high affinity and specificity, preventing the interaction between RANKL andRANK(receptor activator ofnuclear factor-kappa B).Increased osteoclast activity stimulated by RANKL is a key mediator of bone destruction in metastatic bone disease.This leads to a reduction in osteoclast numbers and function, and a decrease in bone resorption, cancer-induced bone destruction.It also leads to a decrease in bone resorption in cortical and trabecular bones.It was developed by the biotechnology companyAmgen.